Literature DB >> 2874327

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein.

M S Einhorn, G A Weinberg, E L Anderson, P D Granoff, D M Granoff.   

Abstract

63 children, aged 2-17 months, were given a new conjugate vaccine composed of the capsular polysaccharide of Haemophilus influenzae type b linked to a Neisseria meningitidis outer-membrane protein. Subjects under 7 months received two injections separated by 1 month, and older subjects received either one or two injections. There were no systemic reactions to this vaccine when it was given with aluminium hydroxide. A single injection of vaccine was highly immunogenic; the geometric mean serum anticapsular antibody concentrations before immunisation and 1 month later were 0.35 microgram/ml and 0.98 microgram/ml for babies of 2-3 months, 0.12 microgram/ml and 1.85 micrograms/ml for those of 4-6 months, and 0.15 microgram/ml and 4.1 micrograms/ml for those of 8-17 months (p less than or equal to 0.003 for each age group). After a second injection of vaccine, 80% and 76% of infants of 2-3 and 4-6 months, respectively, had antibody concentrations greater than 1.0 micrograms/ml. Most subjects showed evidence of IgG responses as measured by enzyme-linked immunosorbent assay. 6-12 months after immunisation, serum antibody levels had fallen (p less than 0.05) but they remained higher than those of unimmunized controls (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874327     DOI: 10.1016/s0140-6736(86)90001-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

2.  Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; K Kristensen; J Henrichsen; C Heilmann
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 3.  Haemophilus influenzae type b vaccine.

Authors:  J R Gilsdorf
Journal:  Indian J Pediatr       Date:  1988 Mar-Apr       Impact factor: 1.967

4.  Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.

Authors:  G J Zigterman; H Snippe; M Jansze; E B Ernste; M J De Reuver; J M Willers
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 5.  Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations.

Authors:  E E Adderson
Journal:  Springer Semin Immunopathol       Date:  2001-12

6.  A major crossreactive idiotype associated with human antibodies to the Haemophilus influenzae b polysaccharide. Expression in relation to age and immunoglobulin G subclass.

Authors:  A H Lucas; D M Granoff
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  New bacterial vaccines for acute respiratory infections.

Authors:  I C Verma
Journal:  Indian J Pediatr       Date:  1987 Mar-Apr       Impact factor: 1.967

8.  Development of serum antibodies of the immunoglobulin G class and subclasses against the capsular polysaccharide of Haemophilus influenzae type b in children and adults with invasive infections.

Authors:  B A Claesson; T Lagergård; B Trollfors
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

9.  Heavy-chain isotype patterns of human antibody-secreting cells induced by Haemophilus influenzae type b conjugate vaccines in relation to age and preimmunity.

Authors:  T Barington; L Juul; A Gyhrs; C Heilmann
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.